139. CRISPR 101 – Starting the Conversation about Gene Editing

This products is free for those who attended FNCE^® 2019.

Gene editing of our food continues to make news, but the groundbreaking pace of newly published research on human genome editing is unprecedented. Over the past few years, CRISPR-Cas9 has been used in human clinical trials to study potential therapies for a wide range of diseases such as cancer and sickle cell anemia. This interview-format session will explore the functionality and use of gene editing tools, the ethical hurdles the technology faces, and the role it may play in human health. It provides a foundation and framework for further exploration of gene editing tools at future FNCEs.

Planned with the Committee for Lifelong Learning

CPEU: 1.0
CPE Level: 1- Basic
Learning Need Codes: 2050, 2060, 1020

Performance Indicators:

• 7.3.1 Recognizes the environmental implications of infectious diseases, compromised health conditions and outbreaks and identifies and implements required preventive action for public safety.
• 8.1.2 Applies knowledge of food and nutrition as well as the biological, physical and social sciences in practice.
• 9.4.7 Demonstrates competent use of technology to enhance the learning experience and delivery of information.

Learning Objectives

• Describe CRISPR and other gene editing tools in terms of what they are and how they work
• Cite the importance of knowing what parts of the genome are responsible for different diseases, and recognize the potential of genome editing for treating and preventing disease in humans.
• Identify at least two ways in which CRISPR and gene editing might be used in clinical practice and be able to distinguish between gene editing and gene therapy.

Moderator

• Meghan Adler, MS, RDN, FAND

Speakers

• Neville Sanjana, PhD